RS
AUTL

R Squared’s Autolus Therapeutics AUTL Stock Holding History

R Squared’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$58.3K Sell
36,426
-3,149
-8% -$4.94K 0.03% 446
2026
Q1 		$54.6K Buy
39,575
+12,915
+48% +$19.6K 0.03% 414
2025
Q4 		$53.1K Sell
26,660
-3,816
-13% -$5.86K 0.02% 455
2025
Q3 		$49.7K Buy
30,476
+8,730
+40% +$17.1K 0.02% 492
2025
Q2 		$49.6K Buy
+21,746
New +$36K 0.03% 395
2025
Q1 		– Sell
-4,680
Closed -$11K – 400
2024
Q4 		$11K Buy
+4,680
New +$15.8K 0.01% 1116

Other funds holding AUTL

MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

R Squared's AUTL Position: Q2 2026 in Review

R Squared reduced its Autolus Therapeutics (AUTL) stake by 8% in Q2 2026, selling an estimated $4.94K and leaving 36,426 shares worth $58.3K. The position accounts for 0.03% of the portfolio, ranked #446.

R Squared first reported a position in AUTL in Q4 2024 and has held it in 6 quarters since. 84 funds tracked by Wall St. Rank hold AUTL as of Q2 2026.

  • R Squared held 36,426 shares of Autolus Therapeutics worth $58.3K as of Q2 2026.
  • R Squared sold 3,149 Autolus Therapeutics shares in Q2 2026, an estimated $4.94K.
  • Autolus Therapeutics made up 0.03% of R Squared's portfolio in Q2 2026, its #446 holding.
  • R Squared first reported a position in Autolus Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 84 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2026.

Based on R Squared's 13F filing for Q2 2026, filed 5 Aug 2026.